A UNSW Sydney-led team of scientists has made an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
By introducing a beneficial natural mutation into blood cells using the gene-editing technique CRISPR, a UNSW Sydney-led team of scientists has been able to switch on production of foetal haemoglobin – an advance that could eventually lead to a cure for sickle cell anaemia and other blood disorders.
People with thalassaemia or sickle cell anaemia have damaged adult haemoglobin – the vital molecule that picks up oxygen in the lungs and transports it around the body – and they require life-long treatment with blood transfusions and medication.
However, people with these diseases who also carry the beneficial natural mutation – known as British-198 – have reduced symptoms, because the mutation switches on the foetal haemoglobin gene that is normally turned off after birth.
The extra foetal haemoglobin in their blood, which has a very strong affinity for oxygen, does the work of the defective adult haemoglobin.
“With CRISPR gene-editing we can now precisely cut and alter single genes within our vast genome,” says study senior author and UNSW molecular biologist Professor Merlin Crossley.
“Our laboratory has shown that introducing the beneficial mutation British-198 into blood cells using this technology substantially boosts their production of foetal haemoglobin.
“Because this mutation already exists in nature and is benign, this ‘organic gene therapy’ approach should be effective and safe to use to treat, and possibly cure serious blood disorders. However, more research is still needed before it can be tested in people,” he says.
The study by scientists from UNSW, the Japanese Red Cross Society and the RIKEN BioResource Centre in Japan, is published in the journal Blood.
The beneficial British-198 mutation, which was first identified in a large British family in 1974, involves a change in just a single letter of the genetic code.
Carriers of this mutation have foetal haemoglobins levels as high as 20% of total haemoglobin, while most people’s foetal haemoglobin levels fall to about 1% of total haemoglobin after birth.
The researchers also discovered how this British-198 mutation works. They found it creates a new binding site for a protein called KLF1 that turns blood genes on.
Mutations affecting adult haemoglobin production are among the most common of all genetic variations, with about 5% of the world’s population carrying a defective gene.
“To turn the new gene editing approach into a therapy for blood disorders, the British-198 mutation would have to be introduced into blood-forming stem cells from the patient,” says Professor Crossley.
“A large number of stem cells would have to be edited in order to repopulate the patients’ blood with genetically enhanced cells.”
The Latest on: Genome therapy
[google_news title=”” keyword=”Genome therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Advancing The Future Of Medicine By Getting Back To Its Genetic Rootson May 9, 2024 at 12:00 pm
“With genetic medicines, we can actually send a therapy inside a cell to change how disease-causing genes are being expressed to potentially treat or prevent disease. These can include introducing ...
- Deaf Baby Girl Hears for First Time in 'Mind-Blowing' Gene Therapy Trialon May 9, 2024 at 11:47 am
Hearing loss affects about 1.5 billion people, while congenital deafness—hearing loss present at birth—affects approximately 1.7 out of every 1,000 children born in the U.S. The OTOF-related deafness ...
- Deaf baby hears for the first time after ‘groundbreaking’ gene therapy trialon May 9, 2024 at 10:22 am
Opal Sandy, an 18-month-old from England, is the youngest child to come close to “normal hearing levels” in a gene therapy trial to aid her genetic deafness.
- Gene therapy breakthrough allows toddler born deaf to hearon May 9, 2024 at 10:03 am
A British toddler born with a genetic condition resulting in deafness can now hear in one ear thanks to a pioneering new gene therapy treatment.
- ASGCT 2024: Kate Therapeutics Unveils Gene Therapy Platform and Product Pipeline Progresson May 9, 2024 at 7:00 am
KateTx debuted less than a year ago with a $51 million Series A round co-led by Westlake Village BioPartners and Versant Ventures.
- Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meetingon May 9, 2024 at 6:00 am
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare ...
- UK girl's hearing restored after groundbreaking gene therapyon May 9, 2024 at 5:41 am
An 18-month old British girl who was born completely deaf is believed to be the youngest person to have their hearing restored after undergoing groundbreaking new gene therapy.
- UK toddler, born completely deaf, hears for first time after pioneering gene therapy: 'It was bonkers'on May 9, 2024 at 1:06 am
A UK toddler's hearing was restored after undergoing the world's first-ever pioneering gene therapy trial. The child was born completely deaf, and the doctors said this development marks a new era in ...
- Deaf toddler can hear after gene therapy world firston May 8, 2024 at 10:03 pm
A deaf toddler is now able to hear after becoming the first patient in the world to receive a new gene therapy.
- Mass Photometry for Gene Therapy Analyticson May 8, 2024 at 1:00 pm
Mass photometry is a high-throughput technique with fast run times in the region of 60 seconds and no need for labeling.
via Google News and Bing News